Skip to main content
Premium Trial:

Request an Annual Quote

Vela Diagnostics Great Basin Platform

Vela Diagnostics has commercialy launched the Great Basin infectious disease diagnostic system in Europe and the US. In preparation for the launch, Vela has relisted the products with the US and Food and Drug Administration and CE-IVD under its name. Initial site placements are evaluating the firm's Stool Bacterial Pathogens Panel. The evaluation will then be followed by Great Basin's five additional assays, including the Staph ID/R Blood Culture panel, Group B Strep Test, Shiga Toxin Direct Test, Bordetella Direct Test, and the Toxigenic C. diff test. All the assays use the Great Basin Analyzer, which is designed to perform automated sample extraction and chip-based detection in a fully enclosed cartridge with integrated data analysis.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.